This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor.

Inclusion Criteria:

• Patients with an advanced solid tumor which has progressed despite standard therapy, or for which no standard therapy exists
• World Health Organization (WHO) performance status ≤ 2
• Patient must meet protocol-specified laboratory values

Exclusion Criteria:

• Patients with brain cancer
• Patients who have concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study
• Patients who have not recovered from previous anti-cancer therapies
• Female patients who are pregnant, breast feeding, or not willing to use an effective method of birth control

Other protocol-defined inclusion/exclusion criteria may apply